Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00289016 · ClinicalTrials.gov registry record · Phase 2
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
A Phase 2 study of Melanoma, sponsored by BioVex Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 8
- Study locations
NCT00289016 is a Phase 2 study of Melanoma that has completed, run by BioVex Limited. The registered enrollment target is 50 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (93% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT00289016, a Phase 2 study of Melanoma, has completed, sponsored by BioVex Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 8
- Study locations
Study Summary
The primary objective of the study was to assess the clinical efficacy of talimogene laherparepvec in terms of tumor response rates.
Conditions Studied
Interventions
- DRUG Talimogene Laherparepvec
Study Locations (8)
California
- UCSD Cancer Center, Thornton Hospital - La Jolla
- UCLA - Los Angeles
Colorado
- University of Colorado, Anschutz Cancer Pavillion - Aurora
Minnesota
- Hubert H Humphrey Cancer Center - Robbinsdale
New Jersey
- Mountainside Hospital - Montclair
New York
- Columbia University, Department of Surgery - New York
Texas
- Mary Crowely Medical Research Center - Dallas
Other
- Royal Marsden Hospital - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2005-12 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00289016
The ClinicalTrials.gov registry entry for NCT00289016 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (93% lower). The listed sponsor is BioVex Limited, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Talimogene Laherparepvec is the first listed.
NCT00289016 reports 8 study locations spanning 7 distinct geographic areas - top geographies include California, Colorado, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00289016 about?
NCT00289016 is a clinical study titled "A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma". The primary objective of the study was to assess the clinical efficacy of talimogene laherparepvec in terms of tumor response rates.
What is the current status of trial NCT00289016?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2005-12. Estimated completion is 2009-05.
What conditions does trial NCT00289016 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT00289016?
The interventions under investigation include: Talimogene Laherparepvec (DRUG).
Who is sponsoring clinical trial NCT00289016?
This trial is sponsored by BioVex Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00289016 being conducted?
This trial has 8 study locations across California, Colorado, Minnesota, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.